Commentary|Videos|July 24, 2025
The Current and Evolving Role of KRAS G12C and Pan-KRAS Inhibitors in Metastatic PDAC
Fact checked by: Chris Ryan
Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.
Advertisement
Advertisement
Related to this article
The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
Frontline Treatment Selection in EGFR-Mutated Non-Small Cell Lung Cancer: Monotherapy Versus Combination Strategies
3
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
4
Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer
5